To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients

The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

Inclusion Criteria:

• Male or female non-childbearing potential Japanese T2DM patients, 30-75 years.
• A body mass index (BMI) of 19 to 27 kg/m2.
• Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment.

Exclusion Criteria:

• Renal dysfunction GFR < 60 mL/min.
• Systolic pressure (SBP) > 160 mmHg or diastolic pressure (DBP) > 95 mmHg
• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP.
• History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.